A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients With Type I Diabetes
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Exenatide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.